凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
海普瑞(002399)公告正文

海普瑞:2012年半年度报告摘要

公告日期 2012-08-03
股票简称:海普瑞 股票代码:002399
                                                             深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    证券代码:002399                             证券简称:海普瑞                            公告编号:2012-050
                                     2012 年半年度报告摘要
                                             一、重要提示
    本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    李锂董事长、单宇董事、李坦董事、解冻独立董事、周海梦独立董事和徐滨独立董事亲自出席董事会会议。许明茵董事因公务出差原因未能亲自出席董事会会议,授权李锂董事长代为出席并行使表决权。
    没有董事、监事、高级管理人员对本报告内容的真实性、准确性和完整性无法保证或存在异议。
    公司半年度财务报告未经会计师事务所审计。
    公司负责人李锂、主管会计工作负责人孔芸及会计机构负责人(会计主管人员) 孔芸声明:保证半年度报告中财务报告的真实、完整。
                                   二、上市公司基本情况(一)基本情况简介
    A 股简称                            海普瑞
    A 股代码                            002399
    上市证券交易所                      深圳证券交易所
                                                 董事会秘书                           证券事务代表
    姓名                                步海华                                熊丹
                                    深圳市南山区高新区中区高新中一道 19 深圳市南山区高新区中区高新中一道 19联系地址
                                    号                                  号
    电话                                0755-26980311                         0755-26980311
    传真                                0755-86142889                         0755-86142889
    电子信箱                            stock@hepalink.com                    stock@hepalink.com
                                                              深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要(二)主要财务数据和指标1、主要会计数据和财务指标以前报告期财务报表是否发生了追溯调整□ 是 √ 否
                                                                                              本报告期末比上年度期末
                                             本报告期末               上年度期末
                                                                                                      增减(%)
    总资产(元)                                   7,878,626,027.84          7,974,312,664.25                      -1.2%
    归属于上市公司股东的所有者权益(元)           7,666,219,030.01          7,816,438,725.07                     -1.92%
    股本(股)                                         800,200,000                  800,200,000                      0%归属于上市公司股东的每股净资产(元/
                                                           9.58                        9.77                   -1.94%股)
    资产负债率(%)                                           1.24%                      0.75%                     0.49%
                                                                                              本报告期比上年同期增减
                                       报告期(1-6 月)                上年同期
                                                                                                        (%)
    营业总收入(元)                                 934,766,914.81          1,573,985,235.43                    -40.61%
    营业利润(元)                                   382,782,067.09           417,008,871.72                      -8.21%
    利润总额(元)                                   382,931,393.47           416,948,153.67                      -8.16%
    归属于上市公司股东的净利润(元)                 329,676,815.22           362,104,760.84                      -8.96%归属于上市公司股东的扣除非经常性损
                                                  329,596,274.9           362,139,664.78                      -8.99%益的净利润(元)
    基本每股收益(元/股)                                      0.41                        0.45                   -8.89%
    稀释每股收益(元/股)                                      0.41                        0.45                   -8.89%
    加权平均净资产收益率(%)                                 4.21%                      4.58%                    -0.37%扣除非经常性损益后的加权平均净资产
                                                          4.21%                      4.58%                    -0.37%收益率(%)
    经营活动产生的现金流量净额(元)                  405,669,401.4           791,976,385.79                     -48.78%每股经营活动产生的现金流量净额(元/
                                                           0.51                        0.99                  -48.48%股)2、非经常性损益项目√ 适用 □ 不适用
                    非经常性损益项目                年初到报告期末金额(元)                     说明
    非流动资产处置损益                                                -181,741.06越权审批或无正式批准文件的税收返还、减免计入当期损益的政府补助(与企业业务密切相关,按照
                                                                   263,158.37国家统一标准定额或定量享受的政府补助除外)计入当期损益的对非金融企业收取的资金占用费企业取得子公司、联营企业及合营企业的投资成本小于取得投资时应享有被投资单位可辨认净资产公允价值产生的收益非货币性资产交换损益委托他人投资或管理资产的损益因不可抗力因素,如遭受自然灾害而计提的各项资产减
                                                               深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要值准备债务重组损益企业重组费用,如安置职工的支出、整合费用等交易价格显失公允的交易产生的超过公允价值部分的损益同一控制下企业合并产生的子公司期初至合并日的当期净损益与公司正常经营业务无关的或有事项产生的损益除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益单独进行减值测试的应收款项减值准备转回对外委托贷款取得的损益采用公允价值模式进行后续计量的投资性房地产公允价值变动产生的损益根据税收、会计等法律、法规的要求对当期损益进行一次性调整对当期损益的影响受托经营取得的托管费收入
    除上述各项之外的其他营业外收入和支出                                 67,909.07其他符合非经常性损益定义的损益项目
    少数股东权益影响额                                                   -40,450.1
    所得税影响额                                                        -28,335.96
    合计                                                                 80,540.32                 --3、同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况□ 适用 √ 不适用4、同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况□ 适用 √ 不适用
                                     三、股本变动及股东情况(一)股本变动情况表√ 适用 □ 不适用
                            本次变动前                  本次变动增减(+,-)                       本次变动后
                                                                 公积金转
                           数量      比例(%) 发行新股   送股                     其他   小计        数量   比例(%)
                                                                   股
                         630,000,0                                                             630,000,0
    一、有限售条件股份                    78.73%                                                                78.73%
                               00                                                                    001、国家持股
                                                                深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要2、国有法人持股
                           630,000,0                                                                 630,000,0
    3、其他内资持股                         78.73%                                                                   78.73%
                                 00                                                                        00
                           630,000,0                                                                 630,000,0
    其中:境内法人持股                      78.73%                                                                   78.73%
                                 00                                                                        00境内自然人持股4、外资持股其中:境外法人持股境外自然人持股5.高管股份
                           170,200,0                                                                 170,200,0
    二、无限售条件股份                      21.27%                                                                   21.27%
                                 00                                                                        00
                           170,200,0                                                                 170,200,0
    1、人民币普通股                         21.27%                                                                   21.27%
                                 00                                                                        002、境内上市的外资股3、境外上市的外资股4、其他
                           800,200,0                                                                 800,200,0
    三、股份总数                              100%                                                                      100%
                                 00                                                                        00(二)前 10 名股东、前 10 名无限售条件股东/流通股股东持股情况表前 10 名股东、前 10 名无限售条件股东持股情况表
    股东总数                                                                                                         39,650前十名股东持股情况
                                                持股比例                  持有有限售条        质押或冻结情况
    股东名称(全称)           股东性质                    持股总数
                                                  (%)                       件股份数量    股份状态           数量
    深圳市乐仁科技有限公司          社会法人股      36.94%     295,562,100     295,560,000深圳市金田土科技有限公
                                 社会法人股      31.87%     255,025,800     255,024,000
                     司
    GS DIRECT PHARMA
                                       外资股     9.42%      75,410,000              0
              LIMITED深圳市水滴石穿科技有限
                                 社会法人股       3.63%      29,016,000      29,016,000
                   公司湖南应时信息科技有限公
                                 社会法人股       3.15%      25,200,000      25,200,000
                     司深圳市飞来石科技有限公
                                 社会法人股       3.15%      25,200,000      25,200,000
                     司中国建设银行-中小企业板
                                 社会法人股       0.12%         995,970              0
    交易型开放式指数基金中国银行-嘉实沪深 300 指
                                 社会法人股        0.11%        844,463              0
         数证券投资基金中国工商银行-华泰柏瑞沪
    深 300 交易型开放式指数          社会法人股       0.09%         754,703              0
           证券投资基金广州融达电源材料有限公
                                 社会法人股       0.08%         647,550              0
                     司前十名无限售条件股东持股情况
                                                                   深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
                                                                                          股份种类及数量
                    股东名称                       持有无限售条件股份数量
                                                                                   种类              数量
            GS DIRECT PHARMA LIMITED                             75,410,000 A 股                                75,410,000中国建设银行-中小企业板交易型开放式指数
                                                                   995,970 A 股                                    995,970
                                    基金
    中国银行-嘉实沪深 300 指数证券投资基金                          844,463 A 股                                    844,463中国工商银行-华泰柏瑞沪深 300 交易型开放
                                                                   754,703 A 股                                    754,703
                      式指数证券投资基金
                    广州融达电源材料有限公司                       647,550 A 股                                    647,550中国工商银行-华夏沪深 300 指数证券投资基
                                                                   607,522 A 股                                    607,522
                                       金中国银行-嘉实沪深 300 交易型开放式指数证
                                                                   500,582 A 股                                    500,582
                               券投资基金
                                       李建奕                      396,282 A 股                                    396,282中信证券股份有限公司客户信用交易担保证
                                                                   346,166 A 股                                    346,166
                                 券账户
                                            代玲                   322,908 A 股                                    322,908
                                             深圳市乐仁科技有限公司和深圳市金田土科技有限公司的股东为李锂
                                         和李坦,深圳市飞来石科技有限公司的股东为李锂,深圳市水滴石穿科技有上述股东关联关系或(及)一致行动人的说明 限公司的股东为单宇和李坦,李锂和李坦为夫妻关系,单宇和李坦为兄妹关
                                         系。除上述情况外,公司未知其他股东之间是否存在关联关系,也未知是否
                                         属于《上市公司收购管理办法》规定的一致行动人。(三)控股股东及实际控制人变更情况□ 适用 √ 不适用
                               四、董事、监事和高级管理人员情况(一)董事、监事和高级管理人员持股变动
                                                                           其中:持有限 期末持有股
                               期初持股数 本期增持股 本期减持股 期末持股数
    姓名            职务                                                   制性股票数 票期权数量                变动原因
                                 (股)   份数量(股)份数量(股) (股)
                                                                             量(股)     (股)
    李锂         董事长                     0              0           0               0        0              0-
    单宇         总经理;董事                0              0           0               0        0              0-
             董事;副总经
    李坦                                    0              0           0               0        0              0-
             理
    许明茵       董事                       0              0           0               0        0              0-
    周海梦       独立董事                   0              0           0               0        0              0-
    解冻         独立董事                   0              0           0               0        0              0-
    徐滨         独立董事                   0              0           0               0        0              0-
    钱欣         监事                       0              0           0               0        0              0-
    唐海均       监事                       0              0           0               0        0              0-
                                                                         深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    苏纪兰          监事                     0               0               0           0          0             0-
    薛松            副总经理                 0               0               0           0          0             0-
    闫晨光          副总经理                 0               0               0           0          0             0-
                副总经理;董
    步海华                                   0               0               0           0          0             0-
                事会秘书
    孔芸            财务总监                 0               0               0           0          0             0-
    张卫华          副总经理                 0               0               0           0          0             0-
                                                 五、董事会报告(一)主营业务分行业、产品情况表
                                                                                                                   单位:元
                                                    主营业务分行业情况
                                                                             营业收入比上年 营业成本比上年 毛利率比上年同
       分行业           营业收入         营业成本            毛利率(%)
                                                                             同期增减(%) 同期增减(%) 期增减(%)
    生物制药               934,180,085.36   573,264,988.64            38.63%             -40.64%        -49.55%        10.84%
                                                     主营业务产品情况
                                                                             营业收入比上年 营业成本比上年 毛利率比上年同
       分产品           营业收入         营业成本            毛利率(%)
                                                                             同期增减(%) 同期增减(%) 期增减(%)FDA 级肝素钠原
                        77,795,780.41    49,573,258.59            36.28%             -73.08%        -75.92%         7.52%料药普通级肝素钠原
                       856,384,304.95   523,691,730.05            38.85%             -33.35%        -43.72%        11.27%料药毛利率比上年同期增减幅度较大的原因说明
    报告期主营业务毛利率较上年同期增长的主要原因是肝素粗品原料采购价格和产品销售价格均下降,公司加强原料采购工作控制营业成本,带来营业成本下降幅度较销售价格下降幅度大,使得主营业务毛利率较上年同期增长10.84%。(二)主营业务分地区情况
                                                                                                                   单位:元
                    地区                                     营业收入                     营业收入比上年同期增减(%)
    国内                                                                     100,138,965.02                            -48.43%
    国外                                                                     834,041,120.34                            -39.55%(三)主营业务及其结构发生重大变化的原因说明□ 适用 √ 不适用(四)主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明√ 适用 □ 不适用
    报告期主营业务毛利率较上年同期增长的主要原因是肝素粗品原料采购价格和产品销售价格均下降,
                                                               深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要公司加强原料采购工作控制营业成本,带来营业成本下降幅度较销售价格下降幅度大,使得主营业务毛利率较上年同期增长10.84%。(五)利润构成与上年相比发生重大变化的原因分析□ 适用 √ 不适用(六)募集资金使用情况1、募集资金使用情况对照表√ 适用 □ 不适用
                                                                                                            单位:万元
    募集资金总额                                                571,747.8 本报告期
                                                                      投入募集                                  5,199.44
    报告期内变更用途的募集资金总额                                      0 资金总额
    累计变更用途的募集资金总额                                        0 已累计投
                                                                    入募集资                                110,807.27
    累计变更用途的募集资金总额比例                                   0% 金总额
                   是否已变                                     截至期末 项目达到                   项目可行
                            募集资金 调整后投          截至期末                   本报告期
    承诺投资项目和超募 更项目                     本报告期          投资进度 预定可使          是否达到 性是否发
                            承诺投资 资总额            累计投入                   实现的效
    资金投向       (含部分                    投入金额          (%)(3)= 用状态日          预计效益 生重大变
                              总额     (1)             金额(2)                      益
                     变更)                                        (2)/(1)  期                         化承诺投资项目年产 5 万亿单位兼符
    合美国 FDA 和欧盟                                                               2012 年
    CEP 标准的肝素纳原 否         29,312.3 29,312.3 3,399.44 7,687.27        26.23% 12 月 31             0否    否
    料药生产建设项目-固                                                             日定资产投资年产 5 万亿单位兼符
    合美国 FDA 和欧盟                                                              2012 年
    CEP 标准的肝素纳原 否        57,164.77 57,164.77       0           0        0% 12 月 31              0否    否
    料药生产建设项目-项                                                            日目流动资金
    承诺投资项目小计    -        86,477.07 86,477.07 3,399.44 7,687.27 -             -                   0-     -超募资金投向
                                                                               2011 年受让成都市海通药业
                   否              720       720       0         720      100% 08 月 30         -92.19 否   否有限公司 36%的股权
                                                                               日
                                                                               2011 年对成都市海通药业有
                   否             1,700     1,700      0       1,700      100% 10 月 20        -217.66 否   否限公司进行增资
                                                                               日
    成立合资公司深圳君                                                             2011 年
    圣泰生物技术有限公 否             2,000     2,000      0       2,000      100% 11 月 15         -65.76 否   否
    司                                                                             日
                                                                               2012 年受让成都深瑞畜产品
                   否             1,800     1,800   1,800      1,800      100% 06 月 10              0否    否有限公司 15%的股权
                                                                               日
    -                                 8,000     8,000      0       8,000      100% -           -           -    -
    补充流动资金(如有)-            88,900    88,900      0      88,900      100% -           -           -    -
    超募资金投向小计    -         103,120     103,120   1,800    103,120 -           -             -375.61 -    -
                                                               深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
                              189,597.0 189,597.0          110,807.2
    合计                 -                            5,199.44           -       -          -375.61 -        -
                                      7         7                  7
                   1、公司承诺募集资金投资项目为年产 5 万亿单位兼符合美国 FDA 和欧盟 CEP 药政标准的肝素钠原
                   料药生产建设项目,投资金额为 86,477.07 万元,其中固定资产投资为 29,312.30 万元,截至 2012
                   年 6 月 30 日已投入 7,687.27 万元,项目流动资金为 57,164.77 万元,截至 2012 年 6 月 30 日尚未投未达到计划进度或预 入。该项目原计划达到可使用状态的时间为 2012 年 7 月 1 日,根据公司第二届董事会第十一次会议计收益的情况和原因 和 2012 年第一次临时股东大会批准,项目达到可使用状态的时间推迟到 2012 年 12 月 31 日。因项
    (分具体项目)     目尚处于建设期,无法计算项目收益。
                   2、深圳君圣泰生物技术有限公司现处在研发期,尚不能产生收益。
                     3、成都市海通药业有限公司报告期内未取得 GMP 证书无法生产销售,尚未产生收益。
                     4、成都深瑞畜产品有限公司 2012 年 6 月正式投入小规模生产,尚未产生收益。项目可行性发生重大
                   无。变化的情况说明
                     √ 适用 □ 不适用
                     1、根据 2010 年 5 月 18 日公司第一届董事会第十八次会议的相关决议,公司使用超额募集资金归还
                     银行贷款 8,000 万元人民币,并补充永久性公司流动资金 40,000 万元人民币;
                     2、根据 2010 年 9 月 13 日公司第一届董事会第二十一次会议的相关决议,公司使用超额募集资金补
                     充永久性公司流动资金 48,900 万元人民币;
                     3、根据 2011 年 7 月 29 日公司第二届董事会第五次会议的相关决议,公司使用超额募集资金 720
                     万元人民币受让子公司成都市海通药业有限公司 36%的股权,2011 年 8 月 30 日,成都市海通药业
                     有限公司完成相关工商备案登记手续,公司对成都市海通药业有限公司持股比例由 49%变更为 85%;超募资金的金额、用途 4、根据 2011 年 8 月 17 日公司第二届董事会第六次会议的相关决议,公司使用超额募集资金 2,000
    及使用进展情况       万元人民币与刘利平博士共同投资在深圳设立药品研究与开发企业,2011 年 11 月 15 日,深圳君圣
                     泰生物技术有限公司在深圳市市场监督管理局办理完成了工商登记注册手续,取得了法人营业执照;
                     5、根据 2011 年 8 月 17 日公司第二届董事会第六次会议的相关决议,公司使用超额募集资金 1,700
                     万元人民币对控股子公司成都市海通药业有限公司进行增资,2011 年 10 月 20 日,成都市海通药业
                     有限公司办理完成有关增资事项及工商变更登记手续,注册资本由人民币 2,000 万元增加至人民币
                     4,000 万元,其中公司出资人民币 3,400 万元,占成都海通 85%的股权比例;
                     6、根据 2012 年 5 月 30 日公司第二届董事会第十五次会议的相关决议,公司使用超额募集资金 1,800
                     万元人民币受让子公司成都深瑞畜产品有限公司 15%的股权,2012 年 6 月 10 日,成都深瑞畜产品
                     有限公司完成相关工商备案登记手续,公司对成都深瑞畜产品有限公司持股比例由 55%变更为 70%。
                   □ 适用 √ 不适用募集资金投资项目实
                   □ 报告期内发生 □ 以前年度发生施地点变更情况
                   □ 适用 √ 不适用募集资金投资项目实
                   □ 报告期内发生 □ 以前年度发生施方式调整情况募集资金投资项目先 □ 适用 √ 不适用期投入及置换情况用闲置募集资金暂时 □ 适用 √ 不适用补充流动资金情况项目实施出现募集资 □ 适用 √ 不适用金结余的金额及原因尚未使用的募集资金
                   尚未使用的募集资金存放于募集资金专项账户。用途及去向募集资金使用及披露中存在的问题或其他 无。情况
                                                             深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要2、变更募集资金投资项目情况表□ 适用 √ 不适用(七)董事会下半年的经营计划修改计划□ 适用 √ 不适用(八)对 2012 年 1-9 月经营业绩的预计2012 年 1-9 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形2012 年 1-9 月归属于上市公司股东的净利润变
                                                                      -20%    至                            0%动幅度2012 年 1-9 月归属于上市公司股东的净利润变
                                                             408,162,386.62   至                 510,202,983.28动区间(万元)2011 年 1-9 月归属于上市公司股东的净利润
                                                                                                 510,202,983.28(元)
                                             由于受到欧美经济低迷和下游制剂市场竞争的影响,肝素钠原料药价格较
    业绩变动的原因说明                           上年同期下降;同时由于受募投项目对产品生产的影响生产量下降,预计
                                             销售量会下降,使得经营业绩较上年同期下降。(九)董事会对会计师事务所本报告期“非标准审计报告”的说明□ 适用 √ 不适用(十)公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明□ 适用 √ 不适用
                                              六、重要事项(一)收购、出售资产及资产重组1、收购资产□ 适用 √ 不适用2、出售资产情况□ 适用 √ 不适用
                                                          深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要3、自资产重组报告书或收购出售资产公告刊登后,该事项的进展情况及对报告期经营成果与财务状况的影响□ 适用 √ 不适用(二)担保事项□ 适用 √ 不适用(三)非经营性关联债权债务往来□ 适用 √ 不适用(四)重大诉讼仲裁事项□ 适用 √ 不适用(五)其他重大事项及其影响和解决方案的分析说明√ 适用 □ 不适用
    2009年6月,公司被认定为高新技术企业(证书编号:GR200944200079)。根据国家对高新技术企业的相关税收政策,公司自获得高新技术企业认定后三年内(2009年至2011年)按照15%的所得税税率征收企业所得税。2011年底,公司高新技术企业认定有效期届满,按照相关复审要求,公司已于2012年5月向深圳市科技创新委员会提交了相关申请复审材料并已被受理。如果复审获得通过,2012年至2014年公司将按照15%的所得税率缴纳企业所得税,否则所得税率将变更为25%。报告期及受理期间,公司暂按照15%的所得税税率缴纳企业所得税。1、证券投资情况□ 适用 √ 不适用2、持有其他上市公司股权情况□ 适用 √ 不适用3、报告期内资金被占用情况及清欠进展情况□ 适用 √ 不适用截止报告期末,上市公司未完成非经营性资金占用的清欠工作的,董事会提出的责任追究方案□ 适用 √ 不适用4、承诺事项履行情况上市公司及其董事、监事和高级管理人员、公司持股 5%以上股东及其实际控制人等有关方在报告期内或持续到报告期内的以下承诺事项√ 适用 □ 不适用
               承诺事项                    承诺人                承诺内容                 履行情况
                                                         深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    股改承诺                           不适用                不适用                   不适用收购报告书或权益变动报告书中所作承
                                   不适用                不适用                   不适用诺
    资产置换时所作承诺                 不适用                不适用                   不适用
                                                          本公司股东深圳市乐仁科
                                                          技有限公司、深圳市金田
                                                          土科技有限公司和深圳市
                                                          飞来石科技有限公司承
                                   公司股东深圳市乐仁科 诺:自公司股票上市之日
                                   技有限公司、深圳市金田 起三十六个月内,不转让 报告期内,承诺人严格履行发行时所作承诺
                                   土科技有限公司、深圳市 或者委托他人管理本公司 了上述承诺。
                                   飞来石科技有限公司     持有的公司股份,也不由
                                                          公司回购本公司持有的公
                                                          司股份。本承诺所指股份
                                                          不包括本公司在此期间新
                                                          增的公司股份。
                                                          一、本公司股东深圳市乐
                                                          仁科技有限公司、深圳市
                                                          金田土科技有限公司和深
                                                          圳市飞来石科技有限公司
                                                          承诺:1、在本公司作为贵
                                                          司控股股东期间,本公司
                                                          保证不自营或以合资、合
                                                          作等方式经营任何与贵司
                                                          现从事的业务有竞争的业
                                                          务,本公司现有的或将来
                                                          成立的全资子公司、控股
                                                          子公司以及其他受本公司
                                                          控制的企业亦不会经营与
                                                          贵司现从事的业务有竞争
                                                          的业务。2、如违反上述承
                                                          诺,本公司同意承担给贵
                                                          司造成的全部损失。二、
                                                          公司股东深圳市乐仁科技
                                                          有限公司和深圳市金田土
                                   公司股东深圳市乐仁科
                                                          科技有限公司承诺:如今
                                   技有限公司、深圳市金田                          报告期内,承诺人严格履行
    其他对公司中小股东所作承诺                                后公司或子公司深圳市多
                                   土科技有限公司和深圳                            了上述承诺。
                                                          普生生物技术有限公司因
                                   市飞来石科技有限公司
                                                          依据深府[1988]232 号文
                                                          享受的企业所得税优惠被
                                                          税务机关撤消而产生的额
                                                          外税项和费用时,将及时、
                                                          无条件、全额返还公司或
                                                          深圳市多普生生物技术有
                                                          限公司补缴的税款以及因
                                                          此所产生的所有相关费
                                                          用。三、公司股东深圳市
                                                          乐仁科技有限公司和深圳
                                                          市金田土科技有限公司承
                                                          诺:如今后公司因以实际
                                                          缴纳的增值税和营业税税
                                                          额为计税依据缴纳城市维
                                                          护建设税和教育费附加事
                                                          宜被税务机关追缴而产生
                                                          额外税项和费用时,将及
                                                          时、无条件、全额返还公
                                                          司补缴的税款以及因此所
                                                             深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
                                                             产生的所有相关费用。四、
                                                             公司股东深圳市乐仁科技
                                                             有限公司和深圳市金田土
                                                             科技有限公司承诺:如今
                                                             后公司或子公司深圳市多
                                                             普生生物技术有限公司因
                                                             上市前执行住房公积金政
                                                             策事宜被要求补缴住房公
                                                             积金、缴纳罚款或因此遭
                                                             受任何损失时,将及时、
                                                             无条件、全额返还公司或
                                                             深圳市多普生生物技术有
                                                             限公司由此遭受的一切损
                                                             失。5、董事会本次利润分配或资本公积金转增预案□ 适用 √ 不适用6、其他综合收益细目
                                                                                                       单位:元
                           项目                                     本期发生额               上期发生额1.可供出售金融资产产生的利得(损失)金额减:可供出售金融资产产生的所得税影响前期计入其他综合收益当期转入损益的净额小计2.按照权益法核算的在被投资单位其他综合收益中所享有的份额减:按照权益法核算的在被投资单位其他综合收益中所享有的份额产生的所得税影响前期计入其他综合收益当期转入损益的净额小计3.现金流量套期工具产生的利得(或损失)金额减:现金流量套期工具产生的所得税影响前期计入其他综合收益当期转入损益的净额转为被套期项目初始确认金额的调整额小计
    4.外币财务报表折算差额                                                       321,288.99             -106,440.97减:处置境外经营当期转入损益的净额
    小计                                                                         321,288.99             -106,440.975.其他减:由其他计入其他综合收益产生的所得税影响前期其他计入其他综合收益当期转入损益的净额小计
    合计                                                                         321,288.99             -106,440.97
                                                                 深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要(六)报告期接待调研、沟通、采访等活动登记表
                                                                                               谈论的主要内容及提供
    接待时间              接待地点           接待方式      接待对象类型            接待对象
                                                                                                       的资料
                                                                               国信证券股份
                                                                               有限公司、广 讨论公司生产经营情况,
                       高新中一道 19 号
    2012 年 01 月 09 日                       实地调研        机构                 州融捷投资管 了解行业趋势和公司发
                       A224 会议室
                                                                               理集团有限公 展战略,未提供书面资料
                                                                               司
                                                                               中国中投证券
                                                                               有限责任公   讨论公司生产经营情况,
                       高新中一道 19 号
    2012 年 02 月 24 日                       实地调研        机构                 司、广州融捷 了解行业趋势和公司发
                       A224 会议室
                                                                               投资管理集团 展战略,未提供书面资料
                                                                               有限公司
                                                                                               讨论公司生产经营情况,
                       高新中一道 19 号
    2012 年 04 月 27 日                       实地调研        个人                 车文申          了解行业趋势和公司发
                       A107
                                                                                               展战略,未提供书面资料
                                                                               国润投资基
                                                                               金、日信证券 讨论公司生产经营情况,
                       高新中一道 19 号
    2012 年 06 月 01 日                       实地调研        机构                 有限公司、广 了解行业趋势和公司发
                       A218 会议室
                                                                               州华阳投资管 展战略,未提供书面资料
                                                                               理合伙企业
                                                                                            谈论公司发展的感悟、历
                    高新中一道 19 号                                           中国高新技术 程、产品、技术优势及对
    2012 年 06 月 20 日                       实地调研        其他
                    A539 会议室                                                产业导报     高新区发展的建议,提供
                                                                                            了公司的介绍材料。
                                                 七、财务报告(一)审计意见半年报是否经过审计□ 是 √ 否(二)财务报表是否需要合并报表:√ 是 □ 否1、合并资产负债表编制单位: 深圳市海普瑞药业股份有限公司
                                                                                                            单位: 元
                项目                  附注               期末余额                               期初余额
    流动资产:
    货币资金                                                    6,682,710,331.68                     6,773,837,875.03
    结算备付金
                           深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    拆出资金
    交易性金融资产                         0                          1,041,964
    应收票据                               0                                 0
    应收账款                    243,069,427.5                    305,412,694.23
    预付款项                   115,218,336.32                     52,196,285.54
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                   111,305,749.36                     67,711,788.29
    应收股利                               0                                 0
    其他应收款                  53,151,747.61                      60,184,886.3
    买入返售金融资产
    存货                       339,737,936.31                    456,493,053.25
    一年内到期的非流动资产
    其他流动资产                           0                                 0
    流动资产合计               7,545,193,528.78                  7,716,878,546.64非流动资产:
    发放委托贷款及垫款
    可供出售金融资产                       0                                 0
    持有至到期投资                         0                                 0
    长期应收款                             0                                 0
    长期股权投资
    投资性房地产
    固定资产                   179,227,021.28                    106,138,676.46
    在建工程                    81,614,983.62                     75,659,238.23
    工程物资                               0                                 0
    固定资产清理                           0                                 0
    生产性生物资产
    油气资产                               0                                 0
    无形资产                     71,125,430.5                     72,038,388.93
    开发支出                      599,845.32                            12,500
    商誉
    长期待摊费用                     300,000                                 0
    递延所得税资产                560,589.14                       3,580,684.79
    其他非流动资产                    4,629.2                           4,629.2
    非流动资产合计               333,432,499.06                    257,434,117.61
    资产总计                   7,878,626,027.84                  7,974,312,664.25流动负债:
    短期借款                               0                                 0
    向中央银行借款                         0                                 0
    吸收存款及同业存放                     0                                 0
    拆入资金                               0                                 0
    交易性金融负债                  3,140,290                                0
                                                    深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    应付票据                                                   239,500                       415,352.8
    应付账款                                           22,918,966.89                      1,629,997.85
    预收款项                                                216,500.86                     215,904.97
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                            328,246.86                   23,398,318.74
    应交税费                                                1,785,688.9                  10,667,495.28
    应付利息                                                         0                              0
    应付股利                                           44,766,002.75                                0
    其他应付款                                          4,140,091.16                       4,103,128.4
    应付分保账款                                                     0                              0
    保险合同准备金                                                   0                              0
    代理买卖证券款                                                   0                              0
    代理承销证券款                                                   0                              0
    一年内到期的非流动负债                                           0                              0
    其他流动负债                                                     0                              0
    流动负债合计                                         77,535,287.42                     40,430,198.04
    非流动负债:
    长期借款                                                         0                              0
    应付债券                                                         0                              0
    长期应付款                                                       0                              0
    专项应付款                                                       0                              0
    预计负债                                                         0                              0
    递延所得税负债                                      8,715,724.75                       9,088,222.6
    其他非流动负债                                     11,202,694.07                       10,458,810
    非流动负债合计                                       19,918,418.82                      19,547,032.6
    负债合计                                             97,453,706.24                     59,977,230.64
    所有者权益(或股东权益):
    实收资本(或股本)                                  800,200,000                       800,200,000
    资本公积                                         5,297,088,191.7                  5,297,185,990.97
    减:库存股
    专项储备
    盈余公积                                          289,428,091.69                    289,428,091.69
    一般风险准备
    未分配利润                                      1,279,384,995.51                  1,429,828,180.29
    外币报表折算差额                                        117,751.11                     -203,537.88
    归属于母公司所有者权益合计                          7,666,219,030.01                  7,816,438,725.07
    少数股东权益                                      114,953,291.59                     97,896,708.54
    所有者权益(或股东权益)合计                         7,781,172,321.6                  7,914,335,433.61负债和所有者权益(或股东权益)
                                                    7,878,626,027.84                  7,974,312,664.25总计
    法定代表人:李锂                 主管会计工作负责人:孔芸                       会计机构负责人:孔芸
                                        深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要2、母公司资产负债表
                                                                                   单位: 元
              项目          附注   期末余额                         期初余额流动资产:
    货币资金                              6,373,558,290.03                 6,610,843,169.94
    交易性金融资产                                                                 1,041,964
    应收票据
    应收账款                               242,834,529.93                    305,557,551.82
    预付款项                                    95,369,749.01                   33,891,606.89
    应收利息                                   111,305,749.36                   68,042,204.96
    应收股利
    其他应收款                                   84,244,078.1                   89,956,925.69
    存货                                       318,611,714.95                456,081,771.27
    一年内到期的非流动资产
    其他流动资产                                 110,000,000                      30,000,000
    流动资产合计                            7,335,924,111.38                 7,595,415,194.57非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                           356,455,948.99                    217,306,448.99
    投资性房地产
    固定资产                                    42,151,834.08                   45,725,367.94
    在建工程                                    35,038,972.13                   14,176,737.98
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                     2,996,450.84                    2,480,168.29
    开发支出                                      599,845.32                          12,500
    商誉
    长期待摊费用                                           0
    递延所得税资产                                514,686.76                     3,507,670.54
    其他非流动资产
    非流动资产合计                           437,757,738.12                    283,208,893.74
    资产总计                                 7,773,681,849.5                 7,878,624,088.31流动负债:
    短期借款                                               0                               0
    交易性金融负债                                 3,140,290
    应付票据
    应付账款                                     4,839,339.73                     851,707.31
    预收款项                                      216,500.86                      215,904.97
                                             深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    应付职工薪酬                                     220,837.54                     23,359,137.99
    应交税费                                        7,091,437.59                    12,415,107.13
    应付利息                                       44,766,002.75
    应付股利
    其他应付款                                      3,405,947.38                     2,992,519.51
    一年内到期的非流动负债                                    0                                0
    其他流动负债
    流动负债合计                                     63,680,355.85                    39,834,376.91
    非流动负债:
    长期借款                                                  0                                0
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债                                                                     156,294.6
    其他非流动负债                                    3,375,000                        2,550,000
    非流动负债合计                                      3,375,000                       2,706,294.6
    负债合计                                         67,055,355.85                    42,540,671.51
    所有者权益(或股东权益):
    实收资本(或股本)                              800,200,000                      800,200,000
    资本公积                                  5,297,861,938.88                 5,294,298,698.88
    减:库存股
    专项储备
    盈余公积                                   289,428,091.69                    289,428,091.69
    未分配利润                                1,319,136,463.08                 1,452,156,626.23
    外币报表折算差额
    所有者权益(或股东权益)合计                7,706,626,493.65                  7,836,083,416.8
    负债和所有者权益(或股东权
                                               7,773,681,849.5                 7,878,624,088.31益)总计3、合并利润表
                                                                                        单位: 元
               项目              附注   本期金额                         上期金额
    一、营业总收入                                 934,766,914.81                  1,573,985,235.43
    其中:营业收入                             934,766,914.81                  1,573,985,235.43
          利息收入
          已赚保费
          手续费及佣金收入
    二、营业总成本                                 547,802,593.72                  1,157,169,141.78
    其中:营业成本                             575,618,102.42                  1,136,393,502.92
          利息支出
          手续费及佣金支出
                                                            深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                                    21,550,306.16                     20,035,429.68
             销售费用                                           2,430,373.62                      2,496,723.76
             管理费用                                          60,945,841.67                     52,240,691.96
             财务费用                                        -112,646,796.46                    -53,997,206.54
             资产减值损失                                         -95,233.69                                0
    加      :公允价值变动收益(损
                                                                  -4,182,254                       192,778.07失以“-”号填列)
             投资收益(损失以“-”
                                                                          0                                 0号填列)
          其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                            382,782,067.09                    417,008,871.72
       加   :营业外收入                                          340,800.99                       181,493.09
       减   :营业外支出                                          191,474.61                        242,211.14
             其中:非流动资产处置
                                                                  181,741.06                        137,211.14损失四、利润总额(亏损总额以“-”号
                                                              382,931,393.47                    416,948,153.67填列)
       减:所得税费用                                          57,859,034.47                     55,851,838.74
    五、净利润(净亏损以“-”号填列)                              325,072,359                     361,096,314.93
    其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利
                                                              329,676,815.22                    362,104,760.84润
       少数股东损益                                            -4,604,456.22                     -1,008,445.91
    六、每股收益:                                         --                                  --
       (一)基本每股收益                                               0.41                              0.45
       (二)稀释每股收益                                               0.41                              0.45
    七、其他综合收益                                                  321,288.99                       -106,440.97
    八、综合收益总额                                              325,393,647.99                    360,989,873.96
    归属于母公司所有者的综合
                                                              329,998,104.21                    361,998,319.87收益总额
       归属于少数股东的综合收益
                                                               -4,604,456.22                     -1,008,445.91总额本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元。
    法定代表人:李锂                       主管会计工作负责人:孔芸                         会计机构负责人:孔芸
                                                            深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要4、母公司利润表
                                                                                                       单位: 元
               项目                  附注       本期金额                                上期金额
    一、营业收入                                                  934,466,688.32                     1,573,984,574.43
    减:营业成本                                             573,381,485.23                     1,136,197,730.91
         营业税金及附加                                        21,474,202.16                       20,029,367.95
         销售费用                                               2,386,407.17                         2,496,723.76
         管理费用                                              42,718,185.31                       47,108,512.14
         财务费用                                            -111,469,611.25                       -53,409,465.98
         资产减值损失                                              13,213.78                                   0
      加:公允价值变动收益(损失
                                                                  -4,182,254                          192,778.07以“-”号填列)
         投资收益(损失以“-”号
                                                                1,702,277.77                                   0填列)
        其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                            403,482,829.69                      421,754,483.72
    加:营业外收入                                              191,242.44                           181,233.09
    减:营业外支出                                                 2,336.06                          137,211.14
         其中:非流动资产处置损
                                                                    2,336.06                          137,211.14失三、利润总额(亏损总额以“-”号
                                                              403,671,736.07                      421,798,505.67填列)
    减:所得税费用                                            56,571,899.22                       55,715,098.38
    四、净利润(净亏损以“-”号填列)                            347,099,836.85                      366,083,407.29
    五、每股收益:                                         --                                  --
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益
    七、综合收益总额                                              347,099,836.85                      366,083,407.295、合并现金流量表
                                                                                                       单位: 元
                 项目                       本期金额                                  上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                      1,015,085,485.62                          1,252,949,351.85
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
                                       深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                   57,983,869.08                        202,115,406.83
    收到其他与经营活动有关的现金     70,818,840.21                         43,140,607.41
    经营活动现金流入小计                1,143,888,194.91                     1,498,205,366.09
    购买商品、接受劳务支付的现金    553,474,829.12                        529,120,531.98
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                      65,864,547.64                         42,940,132.03金
    支付的各项税费                   95,612,919.07                        104,476,684.39
    支付其他与经营活动有关的现金     23,266,497.68                          29,691,631.9
    经营活动现金流出小计                 738,218,793.51                         706,228,980.3
    经营活动产生的现金流量净额            405,669,401.4                        791,976,385.79二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金
    处置固定资产、无形资产和其他
                                             51,430                                2,500长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金                 0                               15,000
    投资活动现金流入小计                         51,430                               17,500
    购建固定资产、无形资产和其他
                                      79,399,478.36                         58,625,648.44长期资产支付的现金
    投资支付的现金
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金                 0                           200,079.09
    投资活动现金流出小计                  79,399,478.36                         58,825,727.53
    投资活动产生的现金流量净额            -79,348,048.36                       -58,808,227.53三、筹资活动产生的现金流量:
    吸收投资收到的现金                  18,000,000                           13,500,000
    其中:子公司吸收少数股东投资
                                         18,000,000                           13,500,000收到的现金
    取得借款收到的现金
    发行债券收到的现金
                                                  深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    收到其他与筹资活动有关的现金                            0                                       0
    筹资活动现金流入小计                                18,000,000                              13,500,000
    偿还债务支付的现金
    分配股利、利润或偿付利息支付
                                                435,353,997.25                          710,200,034.25的现金
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金                            0                                       0
    筹资活动现金流出小计                            435,353,997.25                          710,200,034.25
    筹资活动产生的现金流量净额                     -417,353,997.25                         -696,700,034.25四、汇率变动对现金及现金等价物的
                                                     -94,899.14                            -106,440.97影响
    五、现金及现金等价物净增加额                     -91,127,543.35                          36,361,683.04
    加:期初现金及现金等价物余额              6,773,837,875.03                        6,258,643,300.42
    六、期末现金及现金等价物余额                   6,682,710,331.68                        6,295,004,983.466、母公司现金流量表
                                                                                             单位: 元
               项目                 本期金额                                上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金              1,015,151,642.88                        1,252,949,351.85
    收到的税费返还                              57,983,869.08                          202,115,406.83
    收到其他与经营活动有关的现金                81,752,318.13                           40,754,696.77
    经营活动现金流入小计                           1,154,887,830.09                        1,495,819,455.45
    购买商品、接受劳务支付的现金               537,987,465.81                           490,839,011.4
    支付给职工以及为职工支付的现
                                                 57,290,338.79                            36,543,259.7金
    支付的各项税费                              94,021,682.17                          104,300,332.47
    支付其他与经营活动有关的现金                15,829,474.18                           26,389,188.91
    经营活动现金流出小计                            705,128,960.95                          658,071,792.48
    经营活动产生的现金流量净额                      449,758,869.14                          837,747,662.97二、投资活动产生的现金流量:
    收回投资收到的现金                             30,000,000
    取得投资收益所收到的现金                     2,032,694.44
    处置固定资产、无形资产和其他
                                                         1,430                                   2,500长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                             32,034,124.44                                   2,500
    购建固定资产、无形资产和其他
                                                 34,574,376.24                           17,537,512.69长期资产支付的现金
    投资支付的现金                                249,149,500                              31,265,000
    取得子公司及其他营业单位支付
                                                                深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                                           283,723,876.24                                     48,802,512.69
    投资活动产生的现金流量净额                                     -251,689,751.8                                    -48,800,012.69三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金
    收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                                       0                                                 0
    偿还债务支付的现金
    分配股利、利润或偿付利息支付
                                                               435,353,997.25                                    710,200,034.25的现金
    支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                           435,353,997.25                                    710,200,034.25
    筹资活动产生的现金流量净额                                  -435,353,997.25                                     -710,200,034.25四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                                -237,284,879.91                                       78,747,616.03
    加:期初现金及现金等价物余额                           6,610,843,169.94                                    6,111,239,706.12
    六、期末现金及现金等价物余额                               6,373,558,290.03                                    6,189,987,322.157、合并所有者权益变动表本期金额
                                                                                                                      单位: 元
                                                                     本期金额
                                                  归属于母公司所有者权益
             项目            实收资                                                                        少数股东 所有者权
                                    资本公 减:库存 专项储 盈余公 一般风 未分配                              权益     益合计
                             本(或                                                             其他
                                      积       股     备     积   险准备 利润
                             股本)
                             800,200 5,297,18                  289,428              1,429,82 -203,53 97,896,70 7,914,335,一、上年年末余额
                                ,000 5,990.97                   ,091.69             8,180.29    7.88      8.54     433.61
    加:会计政策变更
           前期差错更正
           其他
                             800,200 5,297,18                  289,428              1,429,82 -203,53 97,896,70 7,914,335,二、本年年初余额
                                ,000 5,990.97                   ,091.69             8,180.29    7.88      8.54     433.61
    三、本期增减变动金额(减少             -97,799.                                      -150,44 321,288. 17,056,58 -133,163,1
    以“-”号填列)                            27                                      3,184.78       99      3.05      12.01
                                                                                    329,676,               -4,604,45 325,072,35(一)净利润
                                                                                      815.22                    6.22          9
                                                                                               321,288.
    (二)其他综合收益                                                                                                  321,288.99
                                                                                                     99
                                                                                    329,676, 321,288. -4,604,45 325,393,64上述(一)和(二)小计
                                                                                      815.22       99      6.22       7.99
                                       -97,799.                                                            21,661,03
    (三)所有者投入和减少资本         0                0      0          0         0         0            0             21,563,240
                                            27                                                                  9.27
                                                               深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
                                                                                                         18,000,00
    1.所有者投入资本                                                                                                  18,000,000
                                                                                                                 0
    2.股份支付计入所有者权益              3,563,24
                                                                                                                     3,563,240
    的金额                                        0
                                       -3,661,0                                                          3,661,0393.其他
                                          39.27                                                                .27
                                                                                   -480,12                           -480,120,0
    (四)利润分配                     0         0      0      0         0         0                     0          0
                                                                                     0,000                                  001.提取盈余公积2.提取一般风险准备
    3.对所有者(或股东)的分                                                          -480,12                           -480,120,0
    配                                                                                   0,000                                  004.其他
    (五)所有者权益内部结转           0         0      0      0         0         0         0           0          0            01.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                             800,200 5,297,08                  289,428             1,279,38 117,751. 114,953,2 7,781,172,四、本期期末余额
                                ,000 8,191.7                    ,091.69            4,995.51       11     91.59     321.6上年金额
                                                                                                                     单位: 元
                                                                    上年金额
                                                  归属于母公司所有者权益
             项目            实收资                                                                      少数股东 所有者权
                                    资本公 减:库存 专项储 盈余公 一般风 未分配                            权益     益合计
                             本(或                                                           其他
                                      积       股     备     积   险准备 利润
                             股本)
                             400,100 5,694,39                  225,474             1,671,89              31,691,59 8,023,563,一、上年年末余额
                                ,000 8,698.88                   ,132.65            9,538.86                   4.56     964.95
    加:同一控制下企业合并产生的追溯调整
    加:会计政策变更
           前期差错更正
           其他
                             400,100 5,694,39                  225,474             1,671,89              31,691,59 8,023,563,二、本年年初余额
                                ,000 8,698.88                   ,132.65            9,538.86                   4.56     964.95
    三、本期增减变动金额(减少 400,100 -397,21                     63,953,              -242,07 -203,53 66,205,11 -109,228,5
    以“-”号填列)              ,000 2,707.91                     959.04             1,358.57    7.88      3.98      31.34
                                                                                   622,082,              -3,144,99 618,937,60(一)净利润
                                                                                     600.47                   3.93       6.54
                                                                                              -203,53                -203,537.8(二)其他综合收益
                                                                                                 7.88                         8
    上述(一)和(二)小计                                                             622,082, -203,53 -3,144,99 618,734,06
                                                                深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
                                                                                   600.47     7.88         3.93        8.66
                                     2,887,29                                                     69,350,10
    (三)所有者投入和减少资本         0                    0   0         0       0         0       0           72,237,400
                                         2.09                                                          7.91
                                       2,217,08                                                       70,020,31
    1.所有者投入资本                                                                                               72,237,400
                                           0.72                                                            9.282.股份支付计入所有者权益的金额
                                       670,211.                                                       -670,211.3.其他
                                            37                                                              37
                                                                63,953,            -864,15                        -800,200,0
    (四)利润分配                     0         0          0   0                 0                 0            0
                                                                 959.04           3,959.04                               00
                                                                63,953,           -63,953,1.提取盈余公积
                                                                 959.04             959.042.提取一般风险准备
    3.对所有者(或股东)的分                                                         -800,20                         -800,200,0
    配                                                                                  0,000                                004.其他
                             400,100 -400,10
    (五)所有者权益内部结转                                0   0         0       0         0       0            0            0
                                ,000   0,0001.资本公积转增资本(或股 400,100 -400,10
    本)                         ,000   0,0002.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                             800,200 5,297,18                   289,428           1,429,82 -203,53 97,896,70 7,914,335,四、本期期末余额
                                ,000 5,990.97                    ,091.69          8,180.29    7.88      8.54     433.618、母公司所有者权益变动表本期金额
                                                                                                                  单位: 元
                                                                      本期金额
              项目           实收资本                                         一般风险 未分配利 所有者权
                                        资本公积 减:库存股 专项储备 盈余公积
                             (或股本)                                         准备     润     益合计
                              800,200,00 5,294,298,                        289,428,09                1,452,156, 7,836,083,一、上年年末余额
                                       0     698.88                              1.69                    626.23     416.8
    加:会计政策变更
           前期差错更正
           其他
                              800,200,00 5,294,298,                        289,428,09                1,452,156, 7,836,083,二、本年年初余额
                                       0     698.88                              1.69                    626.23     416.8
    三、本期增减变动金额(减少                                                                           -133,020,1 -129,456,9
                                            3,563,240
    以“-”号填列)                                                                                          63.15      23.15
    (一)净利润                                                                                         347,099,83 347,099,83
                                                            深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
                                                                                                 6.85        6.85(二)其他综合收益
                                                                                           347,099,83 347,099,83上述(一)和(二)小计
                                                                                                 6.85       6.85
    (三)所有者投入和减少资本              0 3,563,240     0          0           0       0           0 3,563,2401.所有者投入资本2.股份支付计入所有者权益的
                                            3,563,240                                                   3,563,240金额3.其他
                                                                                           -480,120,0 -480,120,0
    (四)利润分配                          0          0    0          0           0       0
                                                                                                  00         001.提取盈余公积2.提取一般风险准备
                                                                                           -480,120,0 -480,120,03.对所有者(或股东)的分配
                                                                                                  00         004.其他
    (五)所有者权益内部结转                0          0    0          0           0       0           0           01.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                              800,200,00 5,297,861,                    289,428,09          1,319,136, 7,706,626,四、本期期末余额
                                       0     938.88                          1.69              463.08     493.65上年金额
                                                                                                        单位: 元
                                                                 上年金额
              项目            实收资本                                         一般风险 未分配利 所有者权
                                         资本公积 减:库存股 专项储备 盈余公积
                              (或股本)                                         准备       润   益合计
                                400,100,00 5,694,398,                  225,474,13          1,676,770, 7,996,743,一、上年年末余额
                                         0     698.88                        2.65              994.87     826.4
    加:会计政策变更
           前期差错更正
           其他
                                400,100,00 5,694,398,                  225,474,13          1,676,770, 7,996,743,二、本年年初余额
                                         0     698.88                        2.65              994.87     826.4
    三、本期增减变动金额(减少以 400,100,00 -400,100,0                     63,953,959          -224,614,3 -160,660,4
    “-”号填列)                        0        00                             .04               68.64       09.6
                                                                                           639,539,59 639,539,59(一)净利润
                                                                                                  0.4        0.4(二)其他综合收益
                                                                                           639,539,59 639,539,59上述(一)和(二)小计
                                                                                                  0.4        0.4
    (三)所有者投入和减少资本              0           0   0          0            0      0            0          0
                                                            深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要
    1.所有者投入资本                      0          02.股份支付计入所有者权益的金额3.其他
                                                                       63,953,959          -864,153,9 -800,200,0
    (四)利润分配                         0          0     0          0                   0
                                                                              .04               59.04        00
                                                                       63,953,959          -63,953,951.提取盈余公积
                                                                              .04                9.042.提取一般风险准备
                                                                                           -800,200,0 -800,200,03.对所有者(或股东)的分配
                                                                                                  00         004.其他
                               400,100,00 -400,100,0
    (五)所有者权益内部结转                                0          0           0       0           0          0
                                        0        00
                             400,100,00 -400,100,01.资本公积转增资本(或股本)
                                      0        002.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
                               800,200,00 5,294,298,                   289,428,09          1,452,156, 7,836,083,四、本期期末余额
                                        0     698.88                         1.69              626.23     416.8(三)报表附注1、主要会计政策、会计估计的变更以及重大会计差错更正及其影响数(1)会计政策变更本报告期主要会计政策是否变更□ 是 √ 否(2)会计估计变更本报告期主要会计估计是否变更□ 是 √ 否(3)会计差错更正本报告期是否发现前期会计差错□ 是 √ 否2、合并报表合并范围发生变更的理由
    报告期内,公司全资子公司海普瑞(香港)有限公司于瑞典新设成立一家全资子公司Heaplink Europe AB;海普瑞(香港)有限公司的全资子公司HISTAR PTE. LTD于上海新设成立了一家全资子公司宇科(上海)医药科技有限公司。
                                                  深圳市海普瑞药业股份有限公司 2012 年半年度报告摘要3、被出具非标准审计报告,列示涉及事项的有关附注□ 是 √ 否
                                                                       深圳市海普瑞药业股份有限公司
                                                                                       董事长:李锂
                                                                                       2012年8月1日
数据加载中...
prevnext
手机查看股票